此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

This Study Will Evaluate if the Field Force Pulsed Field Ablation System is Safe and Effective for Treating Sustained Monomorphic Ventricular Tachycardia, a Potentially Serious Fast Heart Rhythm of the Heart. The Treatment Uses Short Pulses of Energy to Target and Destroy the Heart Tissue Causing VT

2026年9月14日 更新者:Field Medical

Pivotal Study to Evaluate Catheter Ablation in Patients With Scar-Related Monomorphic Sustained VT in the Ventricular Ectopy and Reduction in Tachycardia Ablation Studies Program (VERITAS SCAR VT)

The VERITAS VT Study is a prospective, multicenter, international, single-arm clinical investigation designed to evaluate the safety and effectiveness of the FieldForce™ Pulsed Field Ablation System for the treatment of sustained monomorphic ventricular tachycardia (VT). Eligible patients undergoing catheter ablation for VT will receive treatment with the investigational pulsed field ablation system according to the study protocol.

The study will assess acute and chronic outcomes including major adverse events, freedom from recurrent ventricular tachycardia, need for antiarrhythmic drug escalation, repeat ablation procedures, and other clinically relevant outcomes through 180 days following the index ablation procedure.

研究概览

详细说明

Ventricular tachycardia remains a significant source of morbidity and mortality among patients with structural heart disease. Although catheter ablation is an established therapeutic option, long-term recurrence rates remain substantial and procedural challenges continue to exist.

The VERITAS VT Study is a prospective, multicenter, single-arm clinical investigation evaluating the safety and effectiveness of the Field Force Pulsed Field Ablation System in subjects with sustained monomorphic ventricular tachycardia. Eligible participants will undergo mapping and ablation using the Field Force Pulsed Field Ablation System during the index procedure. Subjects will be followed for 180 days after the index procedure to assess safety and effectiveness outcomes.

The primary safety objective is to evaluate the incidence of device- and procedure-related major adverse events. The primary effectiveness objective is to evaluate freedom from recurrence of sustained monomorphic ventricular tachycardia through 180 days following the index ablation procedure

研究类型

介入性

注册 (估计的)

180

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Signed patient informed consent form (ICF).
  2. Female and male patients aged ≥ 18 and ≤ 85 years.
  3. Implantable Cardioverter-Defibrillator (ICD) implanted ≥ 180 days prior to enrollment.
  4. Clinically Indicated for ventricular tachycardia (VT) ablation by 2019 guidelines:

    • At least one (1) episode of VT, defined as continuous VT lasting > 30 seconds or requiring termination due to hemodynamic compromise, detected by an implanted ICD ≤ 180 days prior to enrollment and
    • Refractory to, contraindicated or intolerant of at least one (1) Class I or III Antiarrhythmic Drug (AAD)
  5. Sustained scar-related monomorphic ventricular tachycardia (MMVT):

    • Objective evidence of ventricular scar confirmed by imaging (magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), intracardiac echocardiography/ transesophageal echocardiogram (ICE/TEE) and/or electro anatomical mapping (EAM)) Or
    • Prior myocardial infarction (MI)
  6. Left ventricular ejection fraction (LVEF) ≥ 20% confirmed by echocardiography or comparable imaging techniques within 180 days prior to enrollment or during baseline evaluation.

Exclusion Criteria:

Subjects will be excluded if ANY of the following apply:

  1. VT secondary to reversible causes (e.g. electrolyte abnormalities, drug or alcohol-induced arrhythmia or non-cardiac cause).
  2. VT ablation within 14 days prior to enrollment.
  3. Greater than three (3) VT ablations within one (1) year prior to enrollment.
  4. Ventricular fibrillation (VF), polymorphic VT or Torsades de Pointes (TdP) as primary clinical arrhythmia.
  5. Bundle branch reentry (BBR), Idiopathic, Para-Hisian or Fascicular VT.
  6. For non-ischemic cardiomyopathy (NICM) if the following apply:

    • Active (within 120 days) inflammatory process (e.g. myocarditis)
    • Sarcoidosis
    • Hypertrophic cardiomyopathy (HCM)
    • Laminopathy (LMNA-related cardiomyopathy)
    • Brugada syndrome (BrS)
    • Amyloidosis
  7. Acute myocardial infarction ≤ 90 days prior to enrollment.
  8. Recent cardiac intervention ≤ 90 days prior to enrollment including but not limited to Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG), lead revision or upgrade, etc.
  9. Implanted with a ventricular assist device (VAD).
  10. Severe mitral or aortic regurgitation or stenosis evaluated by echo or comparable technique.
  11. Presence of an aortic or mitral mechanical valve.
  12. New York Heart Association (NYHA) Class IV heart failure.
  13. Uncontrolled abnormal bleeding and/or clotting disorder.
  14. Contraindication to systemic or oral anticoagulation.
  15. Presence of active intracardiac thrombus detected by imaging (pre-procedural via transesophageal echocardiogram (TEE) or transthoracic echocardiogram (TTE), CT, MRI, or intra-procedural via intracardiac echocardiography (ICE).
  16. Ineligible for ablation according to physician judgement (including but not limited to hemodynamically unstable, prior interatrial patch, Amplatzer, etc.).
  17. Serious or untreated medical conditions that would prevent participation in the study interfere with assessment or therapy, or confound data or its interpretation, including but not limited to solid organ or hematologic transplant, or currently being evaluated for an organ transplant.
  18. Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea at the time of enrollment.
  19. Body Mass Index ≥ 40.
  20. Chronic renal insufficiency of estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2.
  21. Active malignancy.
  22. Active systemic infection.
  23. Life expectancy is less than one year.
  24. Prohibitively distorted cardiac anatomy due to congenital heart disease.
  25. Participation in another investigational study that may interfere with the procedure outcomes for this study unless pre-approved by sponsor.
  26. Unable to understand the nature of this study or is unwilling or unable to attend all the study visits.
  27. Pregnancy or planned pregnancy, lactating or any women of childbearing potential who is not on a reliable form of birth control.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Field Force Pulsed Fiel Ablation
Participants will undergo ventricular tachycardia ablation using the Field Force Pulsed Field Ablation System during the index procedure.
The Field Force Pulsed Field Ablation System is an investigational device that delivers non-thermal pulsed electric field energy through a catheter-based platform to ablate targeted cardiac tissue. The system is intended for use during catheter ablation procedures in patients with sustained monomorphic ventricular tachycardia (VT) to treat tissue involved in the initiation and maintenance of the arrhythmia.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Safety Endpoint - Freedom from casual or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure. (Or within 90 days for esophageal events (fistula/perforation)
大体时间:As applicable within 7 days or 90 days after the index ablation procedure
A pre-defined list of device - or procedure-related MAEs, as adjudicated by the Clinical Events Committee (CEC), occurring within 7 days after the index ablation procedure (or within 3 months after the index ablation procedure for any esophago-pericardial fistula/esophageal perforation) will be considered a primary safety event
As applicable within 7 days or 90 days after the index ablation procedure
Primary Effectiveness: Freedom from recurrence of sustained monomorphic VT
大体时间:Through 6 months most the index ablation procedure
Freedom from recurrence of sustained monomorphic VT (MMVT) in the absence of new or increased dose of Class I or III antiarrhythmic drugs (AAD) for any ventricular arrhythmia through 6 months after the index ablation procedure
Through 6 months most the index ablation procedure

次要结果测量

结果测量
措施说明
大体时间
Secondary Effectiveness Endpoint: Percentage of patients with reduced ventricular tachycardia burden
大体时间:6 months post index procedure
Percentage of patients with reduced ventricular tachycardia burden
6 months post index procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Vivek Reddy, MD、Mount Sinai Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2028年2月1日

研究注册日期

首次提交

2026年8月26日

首先提交符合 QC 标准的

2026年8月26日

首次发布 (实际的)

2026年8月31日

研究记录更新

最后更新发布 (实际的)

2026年9月16日

上次提交的符合 QC 标准的更新

2026年9月14日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅